CynergisTek Experiences Growth in Technical Testing and Certification Services
28 September 2021 - 1:00PM
Business Wire
More Organizations Turn to CynergisTek to
Validate Technical Controls and Reduce Risk
CynergisTek (NYSE American: CTEK), a leading cybersecurity firm
helping organizations in highly-regulated industries navigate
emerging security and privacy issues, reports a surge in multiple
contracts for technical testing and certification services under
their Redspin and Backbone Consulting divisions for clients across
various industries including healthcare, technology, and the
financial sector.
The threat landscape continues to expand and become more complex
as attackers use increasingly sophisticated methods of breaching
and exploiting information systems. Recently Crowdstrike reported
in its latest 2021 Threat Hunting Report that attackers have moved
past malware to more stealthy techniques tailor-made to evade
detection. This coupled with other high-profile events like the
Scripps breach and the Memorial Health attack involving the Hive
ransomware has heightened organization's concern for the integrity
of their enterprises. Increased testing, threat hunting, and
certifying systems have taken on new emphasis. “Simply put, it’s
just getting tougher and validating controls or the integrity of
information assets is becoming an imperative,” said Ben Denkers,
Chief Innovation Officer, CynergisTek. “Technical testing and
evaluation of products and controls adds an important layer of due
diligence.”
As a result, CynergisTek has seen an uptick in requests for
technical testing and certification services, including internal
and external penetration testing, web application penetration
testing, and Electronic Prescriptions for Controlled Substances
(EPCS) certification. Due to increased threats and regulatory
requirements organizations turn to CynergisTek to perform simulated
attacks against internal and external networks and web applications
to find exploits where adversaries can gain entry to steal data and
intellectual property. These types of services validate the
effectiveness of the investment in the tools and technology
implemented and can provide valuable insight for the security team
to determine where to focus resources and budget. Under the Drug
Enforcement Administration (DEA), practitioners, hospitals, and
pharmacies who prescribe controlled substances electronically need
to verify their systems and processes are conducted properly
through EPCS certification to help reduce America’s substance abuse
problem.
“The breadth of expertise from our Offensive Security and EPCS
teams is meeting the demand from clients who are turning to
CynergisTek for the assurance that these types of services
provide,” says Mac McMillan, CEO and President of CynergisTek.
“Historically, most of our services were assessment-related and the
evolution of greater demand for validation aligns with our strategy
to assist clients to achieve a higher degree of resilience and
offers value-added solutions to drive client expansion and revenue
growth.
About CynergisTek, Inc.
CynergisTek (www.cynergistek.com), is a top-ranked cybersecurity
consulting firm helping organizations in highly-regulated
industries, including those in healthcare, government, and finance
navigate emerging security and privacy issues. CynergisTek combines
intelligence, expertise, and a distinct methodology to validate a
company's security posture and ensure the team is rehearsed,
prepared, and resilient against threats. Since 2004, CynergisTek
has been dedicated to hiring and retaining experts who bring
real-life experience and hold advanced certifications to support
and educate the industry by contributing to relevant industry
associations. For more information, visit www.cynergistek.com or
follow us on Twitter or Linkedin.
Cautionary Note Regarding Forward Looking Statements
This release contains certain forward-looking statements
relating to the business of CynergisTek, Inc.. These
forward-looking statements are within the meaning of Section 27A of
the Securities Act of 1933, as amended (the “Securities Act”) and
Section 21E of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”) and can be identified by the use of forward-looking
terminology such as “believes,” “expects,” “anticipates,” “would,”
“could,” “intends,” “may,” “will,” or similar expressions. Such
forward-looking statements involve known and unknown risks and
uncertainties, including but not limited to uncertainties relating
to product/services development; long and uncertain sales cycles;
the ability to obtain or maintain proprietary intellectual property
protection; future capital requirements; competition from other
providers; the ability of the Company’s vendors to continue
supplying the Company with supplies and services at comparable
terms and prices; the Company’s ability to successfully compete and
introduce enhancements and new features that achieve market
acceptance and that keep pace with technological developments; the
Company’s ability to maintain its brand and reputation and retain
or replace its significant customers; cybersecurity risks and risks
of damage and interruptions of information technology systems; the
Company’s ability to retain key members of management and
successfully integrate new executives; the Company’s ability to
complete acquisitions, strategic investments, entry into new lines
of business, divestitures, mergers or other transactions on
acceptable terms, or at all; potential risks and uncertainties
relating to the existing and ultimate impact of COVID-19, including
the geographic spread, the severity of the virus, the duration of
the COVID-19 outbreak, actions that may be taken by governmental
authorities to contain the COVID-19 outbreak or to treat its
impact, and the potential negative impacts of COVID-19 on the
global economy and financial markets, and other factors that may
cause actual results to be materially different from those
described herein as anticipated, believed, estimated or expected.
Certain of these risks and uncertainties are or will be described
in greater detail in the Company’s Form 10-K and Form 10-Q filings
with the Securities and Exchange Commission, which are available at
http://www.sec.gov. Given the risks and uncertainties, readers
should not place undue reliance on any forward-looking statement
and should recognize that the statements are predictions of future
results which may not occur as anticipated. Many of the risks
listed above have been, and may further be, exacerbated by the
COVID-19 pandemic, including its impact on the healthcare industry.
Actual results could differ materially from those anticipated in
the forward-looking statements and from historical results, due to
the risks and uncertainties described herein, as well as others not
now anticipated. CynergisTek is under no obligation (and expressly
disclaims any such obligation) to update or alter its
forward-looking statements whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210928005443/en/
Investor Relations Contact: CynergisTek, Inc. Paul
Anthony InvestorRelations@cynergistek.com
Media Contact: Allison + Partners Jaime Tero 415-755-8639
jaime.tero@allisonpr.com
CynergisTek (AMEX:CTEK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
CynergisTek (AMEX:CTEK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024